Maduck Sean sold $2.3M of CORT

Maduck Sean (See Remarks) sold 20,305 shares of CORCEPT THERAPEUTICS INC (CORT) at $114.70 ($2.33M total) on 2026-08-03 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Maduck Sean
Published Aug 5, 2026, 9:51 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 5, 2026, 9:52 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$CORT
Neutral
high confidence
Mentioned
$CORT
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CORTNeutralLow
01

Why it matters

The newest concrete fact is the disclosed open-market sale size, price, and post-transaction holdings. This typically informs sentiment but rarely changes fundamentals.

02

Market read

Traders may briefly reassess sentiment around CORT due to insider selling, but the 10b5-1 structure makes it less likely to drive a sustained repricing.

03

What to watch

The article does not provide broader insider activity history, total insider ownership changes over time, or whether other executives sold/bought around the same period.

Relevance 5/10Novelty 3/10Timing: filed 2026-08-05, sale dated 2026-08-03

Background

The article is an SEC Form 4 insider transaction disclosure for Corcept Therapeutics, reported by an officer and explicitly tied to a pre-arranged 10b5-1 plan.

Company-level read

Ticker impact

$CORTNeutralHigh confidence
Context

Corcept Therapeutics Form 4 shows officer Maduck Sean sold 20,305 shares at $114.7045 on 2026-08-03 under a 10b5-1 plan.

Expected impact

Limited near-term impact; any reaction is likely muted because the sale is pre-arranged under Rule 10b5-1.

Evidence & confidence

The filing is a primary-source Form 4 with a specified sale price, size, and explicit 10b5-1 pre-arrangement, which typically reduces interpretive signal versus discretionary selling.

Market effects

No clear sector read-through from a single routine 10b5-1 sale.

None indicated.

None indicated.

Counterpoint

Even with 10b5-1, repeated insider selling can still coincide with private views on valuation or liquidity needs, so some traders may treat it as a mild negative signal.

Key entities

  • Corcept Therapeutics Inc

    Subject of the Form 4 insider transaction disclosure (CORT).

  • Maduck Sean

    Officer who sold 20,305 shares under a Rule 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$CORTMedAI 8/10

Corcept reports 8-year response in vulvar cancer case study

Corcept Therapeutics (CORT) reported a case study in ESMO Rare Cancers showing an 8-year response to relacorilant plus nab-paclitaxel in a metastatic vulvar cancer patient. The company noted this is a single case and not representative of the broader population. Relacorilant is FDA-approved for platinum-resistant ovarian cancer but not vulvar cancer. Corcept is developing the drug for other cancer types.

$CORTMed

Corcept Therapeutics Inc (CORT) (Q3 2026) Earnings Call Highlights: Revenue Surges 64%

Corcept Therapeutics (CORT) reported Q3 2026 revenue of $91M, up 64% YoY, driven by Lifyorli's growth. Management expects Lifyorli to move earlier in treatment sequences and sees potential for $1B in revenue. The company reiterated its 2026 guidance of $1.1B-$1.2B, citing strong performance in endocrinology and oncology. CEO Belanoff discussed upcoming clinical trials and potential combinations for Lifyorli.

$CORTMedAI 8/10

Corcept Therapeutics Q3 Earnings Call Highlights

Corcept Therapeutics (CORT) reported positive results from its BELLA Phase 2 trial, with relacorilant showing median progression-free survival of 7.2 months and a 59% response rate. The FDA is set to decide on relacorilant's application for Cushing's syndrome by December 17. Corcept also outlined ongoing trials for relacorilant in various cancers and miricorilant in MASH, with results expected by 2027. The company plans to initiate a Phase 3 ALS study next year.